Literature DB >> 28800028

Current status and future direction in the management of malignant melanoma.

Patrick Gladfelter1, Noureldien H E Darwish, Shaker A Mousa.   

Abstract

The incidence of malignant melanoma is increasing rapidly on a global scale. Although some types of melanoma, for example primary cutaneous melanoma, can be managed by surgery, metastatic melanoma cannot and it has a high mortality rate. Both oncogene and immune-targeted strategies have shown marked efficacy in some patients, but their effect on overall survival is still variable. Therefore, newer therapeutic approaches are needed. Fortunately, new advances in molecular medicine have led to an understanding of an individual patient's cancer at the genomic level. This information is now being used in all stages of cancer treatment including diagnosis, treatment selection, and treatment monitoring. This new strategy of personalized medicine may lead to marked shifts in immunotherapeutic treatment approaches such as individualized cancer vaccines and adoptive transfer of genetically modified T cells. This review provides an overview of recent approaches in cancer research and expected impact on the future of treatment for metastatic melanoma.

Entities:  

Mesh:

Year:  2017        PMID: 28800028     DOI: 10.1097/CMR.0000000000000379

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  10 in total

1.  Role of ubenimex as an anticancer drug and its synergistic effect with Akt inhibitor in human A375 and A2058 cells.

Authors:  Xiaoqing Wang; Yang Liu; Rongde Wu; Feng Guo; Lijuan Zhang; Mingyu Cui; Xiangyu Wu; Yongfei Zhang; Wei Liu
Journal:  Onco Targets Ther       Date:  2018-02-22       Impact factor: 4.147

2.  RNAi-mediated IARS2 knockdown inhibits proliferation and promotes apoptosis in human melanoma A375 cells.

Authors:  Dongmei Ma; Song Li; Xiaojuan Nie; Lamei Chen; Nan Chen; Dongsheng Hou; Xiuhong Liu; Binbin Gao
Journal:  Oncol Lett       Date:  2020-05-29       Impact factor: 2.967

Review 3.  Significance of 5-S-Cysteinyldopa as a Marker for Melanoma.

Authors:  Kazumasa Wakamatsu; Satoshi Fukushima; Akane Minagawa; Toshikazu Omodaka; Tokimasa Hida; Naohito Hatta; Minoru Takata; Hisashi Uhara; Ryuhei Okuyama; Hironobu Ihn
Journal:  Int J Mol Sci       Date:  2020-01-09       Impact factor: 5.923

4.  miR-124 Functions As A Melanoma Tumor Suppressor By Targeting RACK1.

Authors:  Congcong Shen; Hui Hua; Lixiong Gu; Shuanglin Cao; Hengji Cai; Xiaodong Yao; Xiaodong Chen
Journal:  Onco Targets Ther       Date:  2019-11-19       Impact factor: 4.147

Review 5.  Precision medicine for gastrointestinal cancer: Recent progress and future perspective.

Authors:  Tasuku Matsuoka; Masakazu Yashiro
Journal:  World J Gastrointest Oncol       Date:  2020-01-15

6.  Inhibitory effect of kaempferol on mouse melanoma cell line B16 in vivo and in vitro.

Authors:  Di Qiang; Cao Ci; Wenbei Liu; Jun Wang; Caifeng He; Bihua Ji; Xuefei Shao
Journal:  Postepy Dermatol Alergol       Date:  2020-04-07       Impact factor: 1.837

7.  Intramedullary Spinal Cord Metastasis as Initial Presentation of Malignant Melanoma: A Unique Case Report and Role of Contrast vs Non-contrast MRI in Its Diagnosis.

Authors:  Abdul Manan; Syed Rizvi; Jyothi Kondlapudi
Journal:  Cureus       Date:  2021-11-18

8.  Rare Stochastic Expression of O6-Methylguanine- DNA Methyltransferase (MGMT) in MGMT-Negative Melanoma Cells Determines Immediate Emergence of Drug-Resistant Populations upon Treatment with Temozolomide In Vitro and In Vivo.

Authors:  Thomas C Chen; Nymph Chan; Radu O Minea; Hannah Hartman; Florence M Hofman; Axel H Schönthal
Journal:  Cancers (Basel)       Date:  2018-09-28       Impact factor: 6.639

9.  Spindle cell melanoma: Incidence and survival, 1973-2017.

Authors:  Zhe Xu; Ping Shi; Feiluore Yibulayin; Lei Feng; Hao Zhang; Alimujiang Wushou
Journal:  Oncol Lett       Date:  2018-08-01       Impact factor: 2.967

10.  Overexpression of RACK1 Predicts Poor Prognosis in Melanoma.

Authors:  Congcong Shen; Hui Hua; Lixiong Gu; Shuanglin Cao; Hengji Cai; Xiaodong Yao; Xiaodong Chen
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.